Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN D&A

D&A at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$1.57M0.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$172.3M+11.6%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$295M-3.3%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's D&A?
Supernus Pharmaceuticals (SUPN) reported D&A of $26.13M in Q1 2026.
How has Supernus Pharmaceuticals's D&A changed year-over-year?
Supernus Pharmaceuticals's D&A increased by 28.2% year-over-year, from $20.38M to $26.13M.
What is the long-term trend for Supernus Pharmaceuticals's D&A?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's D&A has grown at a 31.6% compound annual growth rate (CAGR), from $29.99M to $90.05M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.